BD Receives CE Mark for Next Generation Blood Separation Technology
FRANKLIN LAKES, N.J. , March 1, 2016 /CNW/ -- BD (Becton, Dickinson and Company), a leading global medical technology company, announced today that it obtained the CE mark in Europe for a next-generation blood separation technology that is designed to enhance sample quality, improve laboratory efficiency and reduce laboratory turnaround time.
BD Vacutainer® Barricor™ tube is a single-use, plastic evacuated tube used to collect, separate, transport and process venous blood specimens to obtain high-quality plasma for in vitro diagnostic use.
The design complements BD Vacutainer® evacuated blood collection tubes, and continues the BD heritage of ensuring best practice in the collection, transportation and processing of blood samples. BD Barricor™ tubes are optimized to deliver a high quality plasma sample by reducing cellular content (vs. plasma gel tubes), as a result of the mechanical separator remaining open throughout the centrifugation cycle. It eliminates gel artifacts which can lead to instrument downtime. These factors together with longer sample stability can significantly improve the sample and laboratory workflow.
According to the American Journal of Clinical Pathology, with 60 to 70 percent of the required information on a patient’s chart coming from laboratory test results, there is a high demand for rapid test turnaround time among clinicians.1 BD Barricor tubes deliver a faster time-to-result for patients – with no clotting time required and a reduction in centrifugation time of up to 7 minutes, an overall saving in turnaround time of 37 minutes is possible.
“Laboratory technicians are forced to choose between a clean sample with serum and a fast sample with plasma,” said Lisa Nibauer , vice president and general manager of Global Marketing for BD Life Sciences. “BD Barricor tubes eliminate this tradeoff, providing a cleaner and faster plasma sample than current methods.”
The new BD Vacutainer Barricor Plasma Blood Collection tube has a revolutionary separator technology, providing a cleaner plasma sample with less cellular contamination, meaning the sample is more stable and allows a longer window to conduct testing when compared to existing blood separation tubes.
For more information, please visit: www.bd.com.
About BD
BD is a global medical technology company that is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. BD leads in patient and health care worker safety and the technologies that enable medical research and clinical laboratories. The company provides innovative solutions that help advance medical research and genomics, enhance the diagnosis of infectious disease and cancer, improve medication management, promote infection prevention, equip surgical and interventional procedures, optimize respiratory care and support the management of diabetes. The company partners with organizations around the world to address some of the most challenging global health issues. BD has more than 45,000 associates across 50 countries who work in close collaboration with customers and partners to help enhance outcomes, lower health care delivery costs, increase efficiencies, improve health care safety and expand access to health. For more information on BD, please visit bd.com.
1 Holland , L.L., Smith, L.L., & Blick, K.E. (2005). Reducing laboratory turnaround time outliers can reduce emergency patient length of stay. American Journal of Clinical Pathology, 124, 672-674.
Contacts:
Matt Coppola
BD Public Relations
201.847.7370
matthew_r_coppola@bd.com
Monique N. Dolecki
BD Investor Relations
201.847.5378
Monique_Dolecki@bd.com
SOURCE BD (Becton, Dickinson and Company)
